红毛五加多糖不同组分对小鼠腹腔巨噬细胞免疫功能的研究

本文研究红毛五加多糖不同组分(AHP-I、AHP-II、AHP-III)对小鼠腹腔巨噬细胞免疫调节功能的影响,为进一步阐明红毛五加多糖对小鼠免疫调节作用机制奠定基础。采用不同浓度的3种多糖组分作用于小鼠腹腔巨噬细胞,测定其对巨噬细胞吞噬中性红、释放NO能力、分泌IL-6、TNF-α、IL-1β水平的影响。最后结果是红毛五加多糖的3种不同组分对小鼠免疫细胞有不同的刺激能力。其中,AHP-II可极其显著地增强吞噬细胞的吞噬功能,促进其合成NO,促进巨噬细胞细胞因子的分泌。因此红毛五加多糖能激活小鼠腹腔巨噬细胞,其中,AHP-II是最重要的作用组分。     

红毛五加多糖对大鼠肝细胞免疫损伤的保护作用及其机制

红毛五加属于五加科植物,而五加科植物大多具有调节免疫力的双向调节作用,红毛五加多糖是从中药红毛五加中提取的单一组分,目前关于红毛五加多糖的抑炎作用还少有报道。为了探究红毛五加多糖AHP-Ⅱ对LPS导致的大鼠肝细胞免疫损伤的保护作用及其作用机制,该研究将实验分为空白组、模型组(LPS,40μg·mL^-1)和AHP-Ⅱ低、中、高剂量组(25,50,100μg·mL^-1)五组,以LPS(40μg·mL^-1)来制备大鼠肝细胞免疫损伤模型,先用ELISA方法检测细胞分泌TNF-α的水平及流式检测ROS的含量,来探究AHP-Ⅱ不同剂量对炎症因子的抑制作用,再用western方法检测P-JNK2的蛋白水平来进一步探究AHP-Ⅱ的抑制作用机制。结果表明:低、中、高剂量组的AHP-Ⅱ均可使肝细胞损伤后的TNF-α含量下降。同时,AHP-Ⅱ中、高剂量组均可使损伤后的肝细胞ROS的分泌量下降,且AHP-Ⅱ高剂量组抑制ROS的作用最强。在加入AHP-Ⅱ后,JNK2蛋白的磷酸化水平呈剂量依赖性降低,AHP-Ⅱ高剂量组抑制作用最强。这说明红毛五加多糖AHP-Ⅱ可以通过降低P-JNK2的蛋白含量来抑制炎症因子TNF-α及ROS的水平,以发挥免疫保护作用。     

野生仙人掌多糖对肺鳞癌细胞SK-MES-1 生长的抑制作用

目的:探讨仙人掌多糖对体外肺鳞癌细胞(SK-MES-1)生长抑制作用。方法:体外培养SK-MES-1细胞,四甲基偶氮唑盐(MTT)法观察野生仙人掌多糖对其生长的抑制,计算最低抑制浓度及抑制率;观察不同浓度多糖对细胞形态的影响;SDS-PAGE凝胶电泳简析不同组别蛋白质表达的差异。结果:野生仙人掌多糖24 h和48 h对肿瘤细胞的最低抑制浓度和抑制率分别为0.0625 mg/ml.34.06%和0.0625 mg/ml 35.37%;不同组间蛋白质表达有差异。结论:野生仙人掌多糖对SK-MES-1肺鳞癌细胞有抑制作用。     

红毛五加多糖对腹腔巨噬细胞作用的定量细胞化学研究

中药红毛五加(Acanthopanax giraldii Harms)属五加科植物,本文通过细胞化学定性、定位、定量研究探讨红毛五加多糖(AGPS)对腹腔巨噬细胞的作用及机理。实验证明AGPS能使巨噬细胞数量明显增多,细胞体积增大,伪足增多,吞噬能力增强,细胞内醣类、酸性磷酸酶、三磷酸腺昔酶、酸性酯酶和琥珀酸脱氢酶活性显著增强。用显微分光光度计对上述单个细胞的化学成分进行定量测定。实验组和对照组结果有显著差异。提示红毛五加的扶正固本作用十分明显,本研究为AGPS的应用和作用机理提供了一定的实验依据。     

抗癌肽研究进展

随着全球癌症患病比例的逐年增加,癌症已经成为全球死亡的主要原因和重大的公共卫生问题。抗癌肽能破坏肿瘤细胞膜结构或抑制癌细胞增殖和迁移以及肿瘤血管的形成,几乎不表现溶血性且对正常的人体细胞基本无损伤等优点,已经成为抗肿瘤新药研究的一大热点。抗癌肽主要来源可分为4类:抗菌肽类如牛乳铁蛋白肽(Lfcin B)、天蚕素等,对细菌等微生物具有广谱高效的抑制活性,同时能够抑制多种癌细胞的增殖和生长,诱导癌细胞凋亡;多肽激素类如心房利钠肽(ANP)以及在ANP形成过程中的其他一些多肽,在临床上具有增加血管通透性、降压、利钠、利尿、舒张血管平滑肌、调节水盐平衡和抑制细胞增殖等作用,最近研究发现它们可以直接杀死肿瘤细胞或强力抑制癌细胞DNA的合成,从而抑制癌细胞的生长;多肽毒素类如蜂毒、蛇毒、蝎毒等毒性较强的生物毒素,对多种肿瘤均有抑制作用;内皮抑制素可以抑制肿瘤血管的生成抑制癌细胞的生长和转移。抗癌肽主要通过诱导细胞凋亡、破坏细胞的膜结构,改变细胞周围或细胞内p H以及增强免疫应答等多种机制来抑制癌细胞增殖。综述抗癌肽的来源、抑癌机理,并对抗癌肽的应用前景进行分析,旨为抗癌肽的深入研究和开发应用提供参考。     

威灵仙多糖对舌鳞癌细胞生长抑制作用的研究

目的:探讨威灵仙多糖对人舌鳞癌细胞Tca-8113的体外生长抑制作用。方法:提取分离纯化威灵仙多糖,用噻唑蓝(MTT)法测定在不同浓度威灵仙多糖作用下人舌鳞癌细胞Tca-8113的活力,观察药物对癌细胞的生长抑制作用。结果:威灵仙多糖对Tca-8113的生长具有明显的抑制作用,随着威灵仙多糖浓度的增大或作用时间延长,抑制作用逐渐增强,呈一定的剂量和时间依赖关系。结论:在体外实验中,威灵仙多糖对人舌鳞癌细胞Tca-8113具有明显的杀伤和抑制作用,可进一步研究其作为抗肿瘤药物应用于临床的潜力。     

五加皮及其混乱品种的药理作用研究

本文对刺五加、细柱五加、红毛五加、香加皮的醇提物及红毛五加水提物五种药液的药理作用进行了比较研究。结果如下：（１）分组腹腔注射五种药液对巴豆油引起的小鼠耳部炎症均有显著的抑制作用,其中以红毛五加水提物的抗炎作用最强。（２）灌胃给五种药液只有红毛五加水提物和刺五加醇提物能明显延长小鼠游泳时间。（３）对环磷酰胺所致白细胞数减少的小鼠分组灌胃五种药液,结果表明红毛五加水提物、刺五加醇提物及细柱五加醇提物均有明显的升白作用。（４）在研究五种药液影响巴比妥钠诱导小鼠睡眠的实验中,结果显示灌胃刺五加醇提物能明显延长小鼠的睡眠时间,香加皮和红毛五抓醇提物则明显缩短小鼠的睡眠时间,细住五加醇提物和红毛五加水提物对小鼠睡眠时间无影响。     

海参多糖抑制人肾癌细胞A498的生长转移作用机制

肾细胞癌(RCC)是最常见的恶性癌之一,癌症转移是目前导致肾癌患者死亡的主要原因之一。MMP-9被发现在许多具有侵袭性和转移能力的人类癌症中过表达,其表达和分泌受到NF-κB调控;VEGF在维持原发性癌和转移瘤生长所需的血管生成中发挥重要作用,其表达也受到活化的NF-κB调节。海参的多种活性物质在抗氧化、抗菌和抗癌方面都有出色的作用,而抗癌的主要机制则包括诱导癌细胞凋亡、抑制癌细胞生长、减少癌细胞转移等。本研究通过利用不同浓度的海参多糖处理人肾癌细胞A498,采用MTT细胞增殖实验、粘附实验、迁移实验和小室侵袭实验,研究了海参多糖对A498细胞的生长转移的影响;采用蛋白印记法检测了海参多糖对A498细胞内MMP-9、NF-κBp65和VEGF表达水平的影响。结果表明,海参多糖能够显著抑制A498细胞的增殖活力、粘附能力、迁移能力和侵袭能力,并且全都表现出明显的剂量依赖性;中浓度(100μg/mL)和高浓度(200μg/mL)的海参多糖能够显著下调A498细胞内MMP-9、NF-κBp65和VEGF的表达。这些结果说明海参多糖能有效抑制人肾癌细胞A498的生长、转移和侵袭,可能的机制是通过抑制NF-κB信号通路下调MMP-9和VEGF的表达,从而发挥抗癌细胞转移的作用。     

百里香酚的抗肿瘤作用

目的：观察百里香酚对体外培养的肝癌细胞的抑制作用。方法：体外培养人肝癌细胞（Bel-7402）,采用MTT法、AO/EB荧光染色法观察百里香酚对人肝癌细胞Bel-7402的作用。结果：百里香酚可显著抑制Bel-7402细胞的生长;经百里香酚作用后,肝癌细胞在显微镜形态明显改变。结论：百里香酚能抑制肝癌Bel-7402细胞生长。     

百里香酚的抗肿瘤作用

目的:观察百里香酚对体外培养的肝癌细胞的抑制作用.方法:体外培养人肝癌细胞(Bel-7402),采用MTT法、AO/EB荧光染色法观察百里香酚对人肝癌细胞Bel-7402的作用.结果:百里香酚可显著抑制Bel-7402细胞的生长;经百里香酚作用后,肝癌细胞在显微镜形态明显改变.结论:百里香酚能抑制肝癌Bel-7402细胞生长.     

IL-3和羟基脲协同诱导K562细胞凋亡

本文应用流式细胞分选仪和电子显微镜研究了IL-3和羟基脲对人红白血病细胞株(K562细胞)凋亡的影响.结果显示IL-3和羟基脲分别诱导K562细胞,不能引起细胞凋亡;而IL-3和羟基脲协同诱导K562细胞,可以引起细胞凋亡.用流式细胞仪检测到IL-3和羟基脲协同诱导K562细胞后,DNA含量低于二倍体的细胞数达31.90%,并产生明显的凋亡小峰.同时,IL-3和羟基脲协同诱导K562细胞,可抑制细胞周期中的S期,阻止细胞从S期进入G2/M期,使细胞周期延长,对K562细胞的生长和增殖具有抑制作用.在电镜下可观察到IL-3和羟基脲协同诱导的K562细胞,出现典型的凋亡细胞形态,细胞核内染色质浓缩、凝聚,紧靠在核膜边沿,形成新月形或环状的染色质结构,产生凋亡小体.提示IL-3和羟基脲具有协同效应,IL-3可提高K562细胞对羟基脲的敏感性,并可协同羟基脲诱导K562细胞凋亡.     

Induction of apoptosis in human leukemia K562 cells by cyclic lipopeptide from Bacillus subtilis natto T-2

A new cyclic lipopeptide (CLP) purified from Bacillus subtilis natto T-2 dose dependently inhibited growth in human leukemia K562 cells. The results of fluorescent staining indicated that CLP brought about apoptosis in K562 cells. Flow cytometric analysis also demonstrated that CLP caused dose-dependent apoptosis of K562 cells through cell arrest at G1 phase. Western blotting revealed that CLP-induced apoptosis in K562 cells was associated with caspase-3 and poly(ADP-ribose)polymerase (PARP) protein. It is estimated that CLP inhibited proliferation in K562 cells by inducing apoptosis.     

RPS27a promotes proliferation,regulates cell cycle progression and inhibits apoptosis of leukemia cells

Ribosomal protein S27a (RPS27a) could perform extra-ribosomal functions besides imparting a role in ribosome biogenesis and post-translational modifications of proteins. The high expression level of RPS27a was reported in solid tumors, and we found that the expression level of RPS27a was up-regulated in advanced-phase chronic myeloid leukemia (CML) and acute leukemia (AL) patients. In this study, we explored the function of RPS27a in leukemia cells by using CML cell line K562 cells and its imatinib resistant cell line K562/G01 cells. It was observed that the expression level of RPS27a was high in K562 cells and even higher in K562/G01 cells. Further analysis revealed that RPS27a knockdown by shRNA in both K562 and K562G01 cells inhibited the cell viability, induced cell cycle arrest at S and G2/M phases and increased cell apoptosis induced by imatinib. Combination of shRNA with imatinib treatment could lead to more cleaved PARP and cleaved caspase-3 expression in RPS27a knockdown cells. Further, it was found that phospho-ERK(p-ERK) and BCL-2 were down-regulated and P21 up-regulated in RPS27a knockdown cells. In conclusion, RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells. It appears that drugs targeting RPS27a combining with tyrosine kinase inhibitor (TKI) might represent a novel therapy strategy in TKI resistant CML patients.     

DADS 上调K562 细胞p21WAF1 表达对细胞生长阻抑和凋亡 的实验研究

目的:探讨二烯丙基二硫(DADS)对体外培养的人白血病细胞系K562细胞生长阻抑和凋亡作用及机制。方法:采用MTT分析法检测细胞活性、流式细胞术分析细胞周期及凋亡率、免疫组化检测p21WAF1基因表达。结果:1).DADS在10mg/L～80 mg/L范围内,对K562细胞的抑制作用呈剂量-时间依赖效应;2).不同浓度DADS作用于K562细胞24h后,细胞周期发生了变化:DADS可以将K562细胞阻滞于G2/M期;3).DADS浓度在10mg/L～80mg/L时作用K562细胞24h后,凋亡率逐渐升高,有显著的统计学意义(P<0.05或P<0.01);4).用浓度分别为0mg/L,20mg/L,40mg/L,80mg/L处理K562细胞24h后,p21WAF1蛋白表达上调,有统计学意义(P<0.05或P<0.01),溶媒组和阴性对照组无差别(P>0.05)。结论:DADS有抑制K562细胞增殖和促进K562细胞凋亡的作用。其作用的可能机制与上调细胞周期蛋白依赖性激酶抑制剂p21WAF1表达,从而诱使k562细胞阻滞于G2/M期有关。     

低浓度丰加霉素对人白血病K562细胞集落形成抑制作用的机制研究

目的初步探讨低浓度丰加霉素对人白血病K562细胞集落形成抑制作用的机制。方法甲基纤维素集落形成实验检测低浓度丰加霉素对人白血病K562细胞集落形成能力的影响;CCK-8法检测低浓度丰加霉素对K562细胞的生长抑制率;AnnexinV／PI双染流式细胞仪检测低浓度丰加霉素作用下的K562细胞凋亡率;PI单染流式细胞仪检测药物作用后细胞的周期分布改变;Western免疫印迹和实时定量PCR检测周期相关分子表达水平变化。结果低浓度丰加霉素对人白血病K562细胞具有较强的集落形成抑制作用;可明显抑制K562细胞的生长,呈时间一剂量依赖性;尽管短时间（48h）的药物处理仅出现轻度的细胞凋亡和周期阻滞,但10nmol/L和30nmol/L的丰加霉素长时间（7d）作用后,K562细胞G0／G1期比例分别是（62．3±1．7）％和（76．9±0．7）％,与对照组（38．9±1．1）％相比差异具有高度统计学意义（P〈0．01）;低浓度丰加霉素长时间作用后诱导K562细胞周期相关分子P16蛋白水平和转录水平的高表达。结论丰加霉素在低浓度,长时间作用于人白血病K562细胞后,具有较强的集落形成抑制和生长抑制作用,此作用可能与诱导细胞周期相关分子p16高表达,导致细胞G0／G1期阻滞有关。     

Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells

BCR-ABL kinase activates downstream signaling pathways, including the PI3K-Akt/mTOR and the MAPK pathway. IRS1 has been previously described as constitutively phosphorylated and associated with BCR-ABL in K562 cells, suggesting that IRS1 has role in the BCR-ABL signaling pathways. In this study, we analyzed the effect of IRS1 silencing, by shRNA-lentiviral delivery, in K562 cells, a CML cell line that presents the BCR-ABL. IRS1 silencing decreased cell proliferation and colony formation in K562 cells, which correlates with the delay of these cells at the G0/G1 phase and a decrease in the S phase of the cell cycle. Furthermore, IRS1 silencing in K562 cells resulted in a decrease of Akt, P70S6K and ERK1/2 phosphorylation. Nevertheless, apoptosis was unaffected by IRS1 knockdown and no alterations were found in the phosphorylation of BAD and in the expression of BCL2 and BAX. BCR-ABL and CRKL phosphorylation levels remained unaffected upon IRS1 silencing, and no synergistic effect was observed with imatinib treatment and IRS1 knockdown, indicating that IRS1 is downstream from BCR-ABL. In conclusion, we demonstrated that inhibition of IRS1 is capable of inducing the downregulation of Akt/mTOR and MAPK pathways and further decreasing proliferation, and clonogenicity and induces to cell cycle delay at G0/G1 phase in BCR-ABL cells.     

Activin A-induced differentiation in K562 cells is associated with a transient hypophosphorylation of RB protein and the concomitant block of cell cycle at G1 phase.

The human erythroleukemic cell line, K562, can be induced to differentiate by the addition of activin A, a newly purified protein belonging to the TGF-beta 1 family. The present studies used flow cytometric cell cycle analysis, indirect immunofluorescence staining of the proliferating cell nuclear antigen (PCNA), and thymidine incorporation assay of cell proliferation to study the effects of activin A on the cell cycle during differentiation in K562 cells. Activin A-treated K562 cells were found to undergo a transient block in cell cycle, temporarily halting progression from G1 to S phase. The latter can be observed after approximately 24 hr of incubation with activin A and then disappears after this early stage of induction of differentiation. Cell cycle kinetics analysis using synchronized K562 cells also confirms that in the presence of activin A, K562 cells progress normally through various phases of cell cycle, except that there is prolongation of the G1 phase between 10 to 24 hr of culture. Furthermore, this transient arrest in G1 is correlated with dephosphorylation of a nucleoprotein, the RB gene product, which occurs within 9-24 hr of incubation with activin A; and phosphorylation of RB protein then develops afterward. In addition, these cell cycle-related events are observed to occur earlier than the accumulation of hemoglobins in K562 cells. It is concluded that transient dephosphorylation of RB protein and prolongation of G1 phase of cell cycle precede and accompany erythroid differentiation caused by activin A and chemical inducers, thus constituting part of the mechanism for induction of differentiation in the erythroleukemia cells.     

Constitutive presence of cytochrome c in the cytosol of a chemoresistant leukemic cell line

The release of holocytochrome c (cyt c) from mitochondria into the cytosol is reportedly a landmark of the execution phase of apoptosis. As shown here, the P-glycoprotein- (P-gp) expressing K562/ADR cell line (but not the parental K562 cell line) exhibits both cytosolic and mitochondrial cyt c in the absence of any signs of apoptosis. K562/ADR cells were found to be relatively resistant to a variety of different inducers of apoptosis, and blocking the P-gp did not reverse this resistance. The release of cyt c in non-apoptotic K562/ADR cells was not accompanied by that of any other mitochondrial apoptogenic protein, such as AIF or Smac/DIABLO, and was inhibited by Bcl-2 over expression. In addition, using a cell-free system, we show that mitochondria isolated from K562/ADR cells spontaneously released cyt c. These data suggest that cyt c release may be compatible with the preservation of mitochondrial integrity and function, as well as cell proliferation.     

Mannosylerythritol lipid induces granulocytic differentiation and inhibits the tyrosine phosphorylation of human myelogenous leukemia cell line K562

Mannosylerythritol lipid (MEL), which induced granulocytic differentiation of human promyelocytic leukemia cell line HL60, also induced differentiation of human myelogenous leukemia cell line K562. MEL inhibited insulin-dependent cell proliferation and induced leukocyte esterase activity of K562 cells. MEL markedly increased the differentiation-associated characteristics in granulocytes, such as nitroblue tetrazolium (NBT) reducing ability, expression of Fc receptors, and phagocytic activity of K562 cells. The tyrosine phosphorylation in K562 cells inhibited by MEL. These results suggest that MEL directly down-regulates the tyrosine kinase activities in K562 cells to inhibit the cell proliferation and to induce the differentiation. This revised version was published online in June 2006 with corrections to the Cover Date.     

Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway

Hyperforin is an abundant phloroglucinol-type constituent isolated from the extract of the flowering upper portion of the plant Hypericum perforatum L. The dicyclohexylammonium salt of hyperforin (DCHA-HF) has exhibited antitumor and antiangiogenic activities in various cancer cells. Here, the antitumor effects of DCHA-HF on the chronic myeloid leukemia K562 cell line were investigated for the first time. DCHA-HF exhibited dose- and time-dependent inhibitory activities against K562 cells, with IC(50) values of 8.6 and 3.2 μM for 48 h and 72 h of treatment, respectively, which was more effective than that of the hyperforin. In contrast, little cytotoxic activity was observed with DCHA-HF on HUVECs. DCHA-HF treatment resulted in induction of apoptosis as evidenced from DNA fragmentation, nuclear condensation and increase of early apoptotic cells by DAPI staining analysis, TUNEL assay and Annexin V-FITC/PI double-labeled staining analysis, respectively. Moreover, DCHA-HF elicited dissipation of mitochondrial transmembrane potential that commenced with the release of cytochrome c through down-regulation of expression of anti-apoptotic proteins and up-regulation of expression of pro-apoptotic proteins. DCHA-HF treatment induced activation of the caspase 3, 8, and 9 cascade and subsequent PARP cleavage, and DCHA-HF-induced apoptosis was significantly inhibited by caspase inhibitors. Treated cells were arrested at the G1 phase of the cell cycle and the expression of p53 and p27(Kip1), two key regulators related to cell cycle and apoptosis, was up-regulated. These results suggest that DCHA-HF inhibits K562 cell growth by inducing caspase-dependent apoptosis mediated by a mitochondrial pathway and arresting the cell cycle at the G1 phase. Therefore, DCHA-HF is a potential chemotherapeutic antitumor drug for chronic myeloid leukemia therapy.